Fulgent Genetics, Inc.
$493.71M- Market cap
- $543.43M
- Debt
- +$476.00K
- Cash
- −$50.19M
Capital structure 100% equity / 0% debt · EV / Revenue 1.53x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: FLGT stock price at premium vs ANF $19.75 current versus $14.15 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ANF's multiple
Implied fair value · at FLGT's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: FLGT FY 2025 (ended Dec 31, 2025) · ANF FY 2026 (ended Jan 31, 2026). Fiscal years are not aligned.
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 100% equity / 0% debt · EV / Revenue 1.53x
Capital structure 81% equity / 19% debt · EV / Revenue 1.35x · EV / EBITDA 8.19x
ANF carries the larger enterprise value at $7.08B against $493.71M; ANF trades on the lower EV / Revenue multiple (1.35x vs 1.53x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
FULGENT GENETICS, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Abercrombie & Fitch Co. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.00x
1.08x
Net debt / EBITDA
Leverage against operating earnings
1.15x
0.85x
Cash and equivalents
Liquid reserves on the balance sheet
$50.19M
$784.58M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
NEOGENOMICS INC
FLGT vs NEO
Natera, Inc.
FLGT vs NTRA
Guardant Health, Inc.
FLGT vs GH
EXACT SCIENCES CORP
FLGT vs EXAS
OPKO HEALTH, INC.
FLGT vs OPK
AMERICAN EAGLE OUTFITTERS INC
FLGT vs AEO
GAP INC
FLGT vs GAP
lululemon athletica inc.
FLGT vs LULU
Victoria's Secret & Co.
FLGT vs VSCO
TILLY'S, INC.
FLGT vs TLYS
$476.00K
$1.52B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.